References
- Adlin V. E., Marks D. A., Channick B. J. Spironoloactone and hydrochlorothiazide in essential hypertension. Archives of Internal Medicine 1972; 130: 855
- Altman P. L., Dittmer D. S. Biological Data Book. Federation of American Society for Experimental Biology, Bethesda Maryland 1974; Vol. Ill: 1842–1848
- Curtis C. G. Whole Body Autoradiography. Academic Press, London 1981
- Dittmer D. S. Blood and other Body Fluids. Federation of American Society for Experimental Biology, Washington 1961; 3–5
- Farrelly R. I., Howie R. N., North J. D. K. Use of spironolactone and hydrochloro-thiazide in treatment of oedema. British Medical Journal 1960; 2: 339–343
- Greenbiatt D. J., Koch-Weser J. Gynecomastia and impotence complications of sparonolactone therapy. Journal of the American Medical Association 1973; 223: 82–89
- Hümpel M., Krause W., Hoyer G. -A., Wendt H., Pommerenke G. The pharmacokine-ties and biotransformation of 14C-lisuride hydrogen maleate in rhesus monkey and in man. European Journal of Drug Metabolism and Pharmacokinetics 1984; 9: 347–357
- Kagawa C. M., Cella J. A., Van Arman C. G. Action of new steroids in blocking effects of aldosterone and desoxycorticosterone on salt. Science 1957; 126: 1015–1016
- Karim A. Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability. Drug Metabolism Reviewes 1978; 8: 151–188
- Karim A., Kook C., Zitzewitz D. J., Zagarella J., Dollerty M., Compion J. Species differences in the metabolism and disposition of spironolactone. Drug Metabolism and Disposition 1976; 4: 547–561
- Krause W., Karras J., Seifert W. Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoat-K in healthy man. European Journal of Clinical Pharmacology 1983a; 25: 449–453
- Krause W., Schubert M., Totzek M. Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374, in the monkey (Macaca fascicularis). Prostaglandins. Leukotriens and Medicine 1983b; 11: 325–328
- Liddle G. W. Aldosterone antagonists. Archives of Internal Medicine 1958; 102: 998–1004
- Losert W., Bittler D., Buse M., Casals-Stenzel J., Haberey M., Laurent H., Nickisch K., Schillinger E., Wiechert R. Mespirenone and other 15,16-methylene-17-spirolactones, a new type of steroidal aldosterone antagonist. Arzneimittelforschung 1986; 36(11)1583–1600
- Nickisch K., Bittler D., Laurent H., Casals-Stenzel J., Nishino Y., Schillinger E., Wiechert R. Aldosterone antagonists. 2. New 7x-acetylthio-15,16-methylenespironolactones. Journal of Medicinal Chemistry 1987, in press
- Ramsay L. E., Shelton J. R., Wilkinson D., Tidd M. J. Canrenone—the principal active metabolite of spironolactone. British Journal of Clinical Pharmacology 1976; 3: 607–612
- Sadée W., Abshagen U., Finn C., Rietbrock N. Conversion of spironolactone to canrenone and disposition kinetics of spironolactone and canrenoate-potassium in rats. Naunyn Schmiedeberg's Archives of Pharmacology 1974; 282: 303–318
- Seller R. H., Swartz C. D., Ramirez-Muxo W., Brest A. H., Moyer J. H. Aldosterone antagonists in diuretic therapy. Archives of Internal Medicine 1964; 113: 350–353
- Sherry J. H., O'Donnell J. P., Colby H. D. Conversion of spironolactone to an active metabolite in target tissues: formation of 7-thiospironolactone by microsomal preparations from guinea pig liver, adrenals, kidneys and testis. Life Science 1981; 29: 2227–2736
- Steelman S. L., Brooks J. R., Morgan E. R., Patanelli D. J. Antiandrogenic activity of cpironolactone. Steroids 1969; 14: 449–450
- Tori K., Kondo E. Structure determination of microbiologically hydroxylated A4, 3-oxosteroids by NMR spectroscopy and its applications. Steroids 1964; 4: 713–727
- Zürcher R. F. Die Lage der C-18 und C-19-Methylsignale in Abhängigkeit von den Substituenten am Steroidgerüst. Helvetica Chimica Acta 1963; 46: 2054–2088